Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight. 2018 09 06; 3(17).
— 2018cited by 0position: selected
Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells
Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B. Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. J Clin Invest. 2016 12 01; 126(12):4640-4653.
— 2016cited by 0position: selected
EAG2 potassium channel with evolutionarily conserved function as a brain tumor target
Ge F, Wang DD, Li L, Lin PP, Shuman MA. WITHDRAWN: Enhanced Detection and Phenotypic and Karyotypic in Situ Characterization of Circulating Tumor Cells. Am J Pathol. 2014 Oct 17.
— 2014cited by 0position: selected
Kadoch C, Li J, Wong VS, Chen L, Cha S, Munster P, Lowell CA, Shuman MA, Rubenstein JL. Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma. Clin Cancer Res. 2014 Feb 15; 20(4):1029-41.
— 2014cited by 0position: selected
Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, Batchelor T, Krouwer H, Hwang J, Auerback G, Kadoch C, Lowell C, Munster P, Cha S, Shuman MA, Damon LE. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013 Jan 31; 121(5):745-51.
— 2013cited by 0position: selected
Immunochemotherapy with Intensive Consolidation for Primary CNS Lymphoma: A Pilot Study and Prognostic Assessment by Diffusion-Weighted MRI
Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma
Wieduwilt MJ, Valles F, Issa S, Behler CM, Hwang J, McDermott M, Treseler P, O'Brien J, Shuman MA, Cha S, Damon LE, Rubenstein JL. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res. 2012 Feb 15
— 2012cited by 0position: selected
Huang V, Place RF, Portnoy V, Wang J, Qi Z, Jia Z, Yu A, Shuman M, Yu J, Li LC. Upregulation of Cyclin B1 by miRNA and its implications in cancer. Nucleic Acids Res. 2012 Feb; 40(4):1695-707.
— 2012cited by 0position: selected
Sun C, Su KH, Valentine J, Rosa-Bauza YT, Ellman JA, Elboudwarej O, Mukherjee B, Craik CS, Shuman MA, Chen FF, Zhang X. Time-resolved single-step protease activity quantification using nanoplasmonic resonator sensors. ACS Nano. 2010 Feb 23; 4(2):978-84.
— 2010cited by 0position: selected
So AY, de la Fuente E, Walter P, Shuman M, Bernales S. The unfolded protein response during prostate cancer development. Cancer Metastasis Rev. 2009 Jun; 28(1-2):219-23.
— 2009cited by 0position: selected
Kadoch C, Dinca EB, Voicu R, Chen L, Nguyen D, Parikh S, Karrim J, Shuman MA, Lowell CA, Treseler PA, James CD, Rubenstein JL. Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model. Clin Cancer Res. 2009 Mar 15; 15(6):1989-97.
— 2009cited by 0position: selected
Rubenstein JL, Shen A, Batchelor TT, Kadoch C, Treseler P, Shuman MA. Differential gene expression in central nervous system lymphoma. Blood. 2009 Jan 01; 113(1):266-7; author reply 267-8.
— 2009cited by 0position: selected
Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol. 2008 Jan 01; 26(1):96-105.
— 2008cited by 0position: selected
Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, Issa S, Damon L, Prados M, McDermott M, O'Brien J, Haqq C, Shuman M. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007 Apr 10; 25(11):1350-6.
— 2007cited by 0position: selected
Chan JM, Feraco A, Shuman M, Hernández-Díaz S. The epidemiology of prostate cancer--with a focus on nonsteroidal anti-inflammatory drugs. Hematol Oncol Clin North Am. 2006 Aug; 20(4):797-809.
— 2006cited by 0position: selected
Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, Karch J, Okada C, Hyun W, Parikh S, Haqq C, Shuman M. Gene expression and angiotropism in primary CNS lymphoma. Blood. 2006 May 01; 107(9):3716-23.
— 2006cited by 0position: selected
Tindall D, Horne FM, Hruszkewycz A, Mohla S, Shuman M, Wang Z, Kantoff P. Symposium on androgen action in prostate cancer. Cancer Res. 2004 Oct 01; 64(19):7178-80.
— 2004cited by 0position: selected
Reddy JC, Shuman MA, Aster RH. Quinine/quinidine-induced thrombocytopenia: a great imitator. Arch Intern Med. 2004 Jan 26; 164(2):218-20.
— 2004cited by 0position: selected
Bhatt AS, Takeuchi T, Ylstra B, Ginzinger D, Albertson D, Shuman MA, Craik CS. Quantitation of membrane type serine protease 1 (MT-SP1) in transformed and normal cells. Biol Chem. 2003 Feb; 384(2):257-66.
— 2003cited by 0position: selected